Nile Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing products for the treatment of cardiovascular diseases. Its compound, CD-NP, is a chimeric natriuretic peptide in clinical development for an initial indication of acute decompensated heart failure. The company is also developing CU-NP, which is a chimeric natriuretic peptide in preclinical development.
Partial Data by Infogroup (c) 2024. All rights reserved.